New Triple-Threat attack on deadly prostate cancer
NCT ID NCT06085729
Summary
This early-stage study aims to find the safest and most effective dose of a new drug, ADI-PEG20, when combined with two existing chemotherapy drugs (carboplatin and cabazitaxel). It is for men with a fast-growing, hard-to-treat form of advanced prostate cancer. The goal is to control the cancer and see how well patients tolerate the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.